NGR-hTNF, a novel vascular targeting agent (VTA), as second-line therapy in malignant pleural mesothelioma (MPM): Preliminary results of multicenter phase II study

Authors :: Giovanni Luca Ceresoli
Vanesa Gregorc
Claudio Bordignon
Emilio Bajetta
Antonio Lambiase
Maria Grazia Viganò
Federico Caligaris-Cappio
Antonella Santoro
Cristina Noberasco
Paolo Andrea Zucali
Source :: Journal of Clinical Oncology. 26:8099-8099
Publication Year :: 2008
Publisher :: American Society of Clinical Oncology (ASCO), 2008.
Abstract: 8099 Background: NGR-hTNF is a VTA exploiting a tumor-homing peptide (NGR) that selectively binds to aminopeptidase N/CD13 highly expressed on tumour blood vessels. NGR-hTNF combines direct antican...

Subjects :: Cancer Research
Second-line therapy
Pathology
medicine.medical_specialty
Pleural mesothelioma
business.industry
Aminopeptidase N
Phases of clinical research
chemistry.chemical_compound
Oncology
NGR-hTNF
chemistry
Vascular-targeting agent
Cancer research
Medicine
business

Full Text Access

Tools